On February 28, 2023, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management, LLC, to provide up to CHF 22.2 m in aggregate, subject to certain milestones and conditions. In addition, Santhera issued 40 m shares in an ordinary capital increase, 37 m of which will be held in treasury for the time being.

The Homburger team was led by Daniel Häusermann (Corporate / M&A, Capital Markets) and included Eduard De Zordi (Capital Markets), Stefan Oesterhelt (Tax), Jasmin Künzle and Romain Fakhoury (Corporate / M&A, Capital Markets), as well as Anna Delia Lohmann and Fabio Anceschi (both Corporate / M&A).

Contact

Nanding Susso / Marketing / [email protected]